Official Sections CTRMS ISVCA IPITA IPTA ISODP IRTA IXA SPLIT TID

2016 - TID Conference


This page contains exclusive content for the member of the following sections: TTS, TID

Session 2 : Early Transplant Complications - The First 30 Days

2.0 - Invasive Mold Infection in the Era of Antifungal Prophylaxis

Presenter: Deborah, Marriott, Sydney, Australia
Authors:

IFI in the era of antifungal prophylaxis’ implies a uniform implementation of antifungal prophylaxis in solid organ transplant recipients.  However there is considerable heterogeneity in practice based on a number of factors including:

  • Type of organ transplanted
  • Local fungal epidemiology
  • The incidence of IFI
  • Prior fungal colonization
  • Individual risk factors – rejection, CMV infection, hypogammaglobulinaemia

Antifungal prophylaxis choices include:-

  • No prophylaxis
  • Yeast-active agent
  • Mould-active agent
  • i-v, oral or nebulized route

Strategies include:-

  • Universal prophylaxis (all transplant recipients receive antifungal prophylaxis)
  • Pre-emptive therapy (antifungal therapy commenced following the isolation of a fungus with no evidence of invasive disease)

The choice of strategy will have a significant impact of the nature and type of IFI that occurs.  The timely use of diagnostic techniques such as Aspergillus PCR and the detection of galactomannan allows the implementation of targeted pre-emptive therapy and therefore reduces overall antifungal exposure.  However the utility of biomarkers for screening has yet to be confirmed in the solid organ transplant setting.

Widespread implementation of antifungal prophylaxis comes at a price.  Drug interactions, medication toxicity, financial cost and the emergence of resistant strains of yeast and moulds need to be weighed against the potential reduction in IFI.  If azole antifungal therapy is administered there is general agreement that therapeutic drug monitoring is an important component of optimal patient management and should be available in real time to have an impact on dosing decision making.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Contact

Staff Directory
+1-514-874-1717 , X : 216
sections@tts.org

Address

Transplant Infectious Disease
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada